Features
As the pharmaceutical landscape continues to evolve, this issue highlights use of AI and GAMP® frameworks for different areas of the industry including quality and data management.
Categorization offers a useful starting point for assessing the risk of failure for individual software components, but it is not a validation checklist. Organizations must apply critical thinking to combine categorization with risk assessment and supplier assessments to appropriately scale life cycle activities and manage risk.
This article presents a model for promoting data quality of real-world data and evidence (RWD/RWE) and GxP processes with references to ISO 8000 for data quality management, making it a common language between regulated and nonregulated organizations.
Data integrity drives quality and compliance. Content addressable storage (CAS) stores and retrieves files by content type—not file location—using cryptographic fingerprints. The result: a mathematically provable version control, without broken links and far fewer audit headaches.
A single global digital chemistry, manufacturing, and controls (CMC) dossier is rapidly transitioning from a bold vision to a practical reality. However, realizing the full potential of these innovations requires significant coordination to harmonize and align across initiatives.
To accelerate the adoption of innovation in the global administration of the pharmaceutical industry, regulatory authorities and industry trade organizations must expand their scope and pursue a collaborative approach to recognition and reliance to streamline processes, enhance product quality, and improve patient access to medicines.
Thanabalan “Thana” Subramanian is Head of the Digital Quality team in the quality, regulatory, digital consultancy firm Product Life Group. He is responsible for a team of 20 consultants and supports the Digital Quality Center of Excellence, covering IT compliance, computer software validation (CSV), data integrity, CSV auditing, and CSV training. Before joining Integrity, he worked for...
Frank Henrichmann is an expert in quality management, computerized system validation, and compliance, especially in clinical trials and pharmacovigilance. With over 25 years of experience in quality functions within the pharmaceutical industry, he has gained deep expertise in implementing and validating computerized systems within GxP-regulated environments, having worked with organizations...
The 2025 ISPE D/A/CH workshop on “Pharma’s Journey to Digital Manufacturing and Supply” united pharma leaders, technology experts, and regulatory authorities for three days of intense exchange on the digital transformation of our industry.
Sustainability principles can be effectively integrated into commissioning and qualification (C&Q) projects to support environmental goals without compromising compliance, quality, or patient safety. By positioning C&Q as both a verification tool and an enabler of sustainable intent, this article outlines a practical path for the pharmaceutical sector to enhance operational efficiency,...
The pharmaceutical industry’s embrace of digital technologies and sustainability is no longer a competitive advantage, but an operational necessity. As Pharma 4.0™ matures, its integration will be vital for achieving net-zero objectives and achieving pharmaceutical excellence.
Crafting a sustainable packaging strategy for the pharmaceutical industry is complex and requires balancing environmental responsibility with regulatory compliance and operational costs. In this article, we explore the key drivers, challenges, and best practices for developing such a strategy.
The development of platform drug delivery devices for combination products offers a transformative approach to drug delivery by enabling the reuse of device data across multiple drug and device combinations.
Advancements in technology—such as process intensification, continuous manufacturing, and 3D printing—are enabling transportable and point-of-care (PoC) medicines manufacturing, especially with the rise of personalized medicine. Modular, small-scale production systems are particularly well-suited for cell and gene therapies and other advanced therapy medicinal products (ATMPs) designed for...
Simplified approaches that enable changes to analytical procedures over their lifecycle are needed to allow continual improvements and adaptations due to technological obsolescence and other challenges. This article reflects on the positive impact that the recent ICH Q14 guidance can have on facilitating these changes. Five examples are provided that are based on scenarios in which analytical...
The International Council for Harmonisation (ICH) Q2(R2) and Q14 guidelines, finalized in late 2023, outline strategies for analytical procedure development, validation, and lifecycle management. As global implementation progresses, ISPE’s PQLI® Analytical Method Strategy Team surveyed industry stakeholders in mid-2024 to assess readiness, identify opportunities, and highlight areas...
In April 2023, ISPE launched a survey to understand the sources of barriers to technological innovation within the pharmaceutical industry. This survey is part of an expansive and significant initiative by ISPE, Enabling Global Pharma Innovation: Delivering for Patients, which aims to promote consistent and harmonized interpretation and implementation of guidelines issued by the International...
Defining requirements for calibration and routine testing of weighing equipment in the laboratory and production remains a complex endeavor for pharmaceutical companies. Applying sound, risk-based metrological strategies across the entire pharmaceutical value chain will help manufacturers ensure compliance, consumer safety, and commercial success.
The United States Pharmacopeia (USP) Packaging and Distribution Expert Committee approved chapters 665 and 1665 in 2024. These chapters establish clear and general guidelines for the use of plastic materials in process equipment used within the pharmaceutical and biotechnology industries. Their publication has raised new questions regarding the role of polymeric materials in manufacturing...
The increasing digitalization of the pharmaceutical and medical device industry has created novel cybersecurity challenges, particularly with the rapid advancement of artificial intelligence (AI) technologies. This article examines the dual nature of AI as both a potential threat vector and a powerful defensive tool.
The move to digital transformation represents a true paradigm shift in manufacturing, enabling organizations to leverage advanced technologies such as the Industrial Internet of Things (IIoT), cloud computing, and artificial intelligence (AI) to ensure compliance and secure a competitive advantage. This article presents a working definition of digital transformation, the components involved in...
Currently, there is no single guidance document providing a comprehensive roadmap for executing digital validation. While elements from ISPE GAMP® Guides Series and the ISPE Baseline® Guide: Volume 8 – Pharma 4.0™, apply to digital validation, there is no consolidated resource addressing common questions. The authors of this Concept Paper therefore advocate for the development of a Good...
From the aesthetic integration of technology in historic buildings to the granular details of digital validation, the GEP and GMP Compliant Project Delivery track at the 2026 ISPE Europe Annual Conference offers a comprehensive look at the future of...
Life science facilities are increasingly expanding their laboratory footprints to bring processes in-house, consolidate testing, and optimize underutilized office space. In today’s dynamic business environment, where agility, speed, and cost efficiency are paramount, converting office areas to laboratory space has become a strategic way to streamline operations while maintaining flexibility...
Digital transformation in the pharmaceutical industry is no longer a strategic ambition—it is an operational reality. Artificial intelligence (AI), cloud platforms, and data-driven automation are increasingly embedded in GxP-critical processes, from development and manufacturing to quality assurance and supply chain operations. While technology evolves rapidly, regulatory expectations around...
What if your next digital investment did not deliver the transformation you expected? For many pharma companies, that is the reality.
In the fast-paced world of life sciences, the ability to connect with global experts, solve technical hurdles in real-time, and stay ahead of regulatory shifts is not just a benefit—it is a professional necessity. For years, ISPE Engage has served as the premier digital home for the global ISPE community, acting as the connective tissue between thousands of professionals, regulators, and...
The 2025 ISPE International Honor Awards took place in Charlotte, North Carolina, USA during the 2025 ISPE Annual Meeting & Expo. Hosted during the Membership Meeting and Awards Lunch, the ceremony recognized ISPE members and contributors whose...
In November 2025, the ISPE Nordic Affiliate gathered at Novo Nordisk in Bagsværd, Denmark, to explore a simple but powerful question: What is your purpose—and what drives you?
The ISPE Guide: ATMPs – Allogeneic Cell Therapy centers on allogeneic cell therapies, with a special focus on manufacturing facility development and design. The Guide provides answers to common challenges faced in allogeneic cell therapy facilities,...
As the pharmaceutical landscape undergoes rapid and profound transformation, the role of regulatory and quality professionals has never been more critical. At the 2026 ISPE Europe Annual Conference in Copenhagen, Denmark, 20–22 April, the Regulatory...
EU GMP Annex 1 has pushed sterile manufacturing conversations from “what does it mean?” to “how is it proven?” Annex 1 requires a facility-wide, integrated contamination control strategy (CCS) that defines critical control points, verifies the effectiveness of design and operational controls, and is actively reviewed to drive continual improvement.
The revised EU GMP Annex 1 has placed renewed emphasis on developing a holistic approach to contamination control: leveraging barrier technologies, automation, rapid microbial methods and proactive management of airflow patterns, compelling manufacturers to rethink how aseptic systems are designed, qualified, and operated. With these evolving regulatory expectations and growing complexity in...
As facility design, manufacturing platforms, and digital systems continue to leap forward, regulators expect quality to keep up. At the 2026 ISPE Facilities of the Future Conference, the brand-new Compliance and Quality track puts that focus front and...
Pharma companies are currently experiencing unprecedented challenges as a result of external factors such as geopolitics, the adoption of new modalities, rapidly changing technologies including digital ones, and also regulatory changes. In order to overcome these challenges, the pharmaceutical industry must accelerate and embrace new technologies, approaches and thinking. Hence to grow and...
The 2026 ISPE Facilities of the Future Conference is set to take place 2–3 February in San Diego, California, USA. The conference will focus on the future of pharmaceutical manufacturing, with dedicated technical tracks on compliance and quality;...
The 2025 ISPE International Honor Awards were held during the Membership Meeting and Awards Lunch during the 2025 ISPE Annual Meeting & Expo in Charlotte, North Carolina, USA. The ceremony recognized ISPE members and contributors whose dedication and service exemplify what it means to Shape the Future of Pharma™. The Emerging Leader Member of the Year Award was presented to Ryan Mazur and...
In the biopharmaceutical industry, the world is changing faster than buildings can be built. Companies are being asked to deliver breakthrough therapies, expand capacity, diversify modality pipelines, decarbonize operations, meet ever-shifting regulatory expectations, and stay globally competitive—all while maintaining reliability, safety, and cost control.
The evolution of pharmaceutical manufacturing has progressed through several stages—from manual drug compounding to fully automated lines with rigorous quality control. Today, a new era—Pharma 4.0™—is unfolding, offering both transformative opportunities and complex challenges driven by market needs, regulatory requirements, and rapid digital innovation.
Sponsored content is the sole responsibility of the authors and is not endorsed, reviewed, nor a published article of Pharmaceutical Engineering® magazine or ISPE.
The versatility of a Portable TOC Analyzer provides users ultimate efficiency gains in cleaning validation and product changeover
Maintaining cold chain integrity is essential to preserve the safety, stability, and therapeutic performance of biologics throughout bioprocessing. Freezing, cold storage, and thawing have a considerable impact on protein stability, making precise process control critical in preventing cryoconcentration, structural degradation, and batch inconsistency.
Whether networking at events or collaborating through our Communities of Practice, the value of an ISPE membership is in the connections made between pharmaceutical industry professionals and Regulators to collaborate on solutions to common goals and challenges.
Are you a subject-matter expert in the global pharmaceutical industry? Are you brimming with knowledge about the latest technical developments or regulatory initiatives? Have you found an innovative solution to a real-world challenge?
Contribute your knowledge and experience to the always-evolving pharmaceutical industry!
Do you know someone whose profile or work should be featured in Pharmaceutical Engineering? Contact ISPE Publications Department.